AbbVie (NYSE: ABBV – Get Rating) updated its FY22 earnings guidance on Friday. The company put forward his EPS guidance for the period at $13.70 to $13.74, compared to a consensus EPS estimate of $13.85. AbbVie also updated its guidance for fiscal year 2022 to his EPS of $13.70 to $13.74.
Wall Street analyst opinion
Several equity analysts recently published reports on the company. Barclays lowered AbbVie’s price target from $160.00 to $155.00 in its report on Monday, October 31, setting the company’s valuation at par. StockNews.com began covering AbbVie in an investigative report on Wednesday, October 12. They set a strong buy rating on the company. SVB Leerink lowered its price target for AbbVie shares from $140.00 to $135.00, setting the stock’s valuation to underperform in a research report on Friday, Sept. 30. Did. Atlantic Securities lowered its price target on AbbVie from $162.00 to $157.00 in its research notes on Monday, October 31, giving the stock a neutral rating. Finally, Morgan Stanley raised its price target on AbbVie stock from his $178.00 to $182.00, giving it an Overweight rating in its research note on Tuesday, Dec. 6. Equity Research 1 of his analysts gave the stock a sell rating, 7 gave a hold rating, 6 assigned a buy rating, and 1 assigned a strong buy rating to the company’s stock. I was. According to MarketBeat data, the company’s current average rating is Hold, with a consensus target price of $159.89.
AbbVie price performance
ABBV rose $3.06 in Friday trading to reach $166.55. His 5,042,686 shares in the company were exchanged, but the average trading volume was 4,498,141 of his shares. AbbVie’s 12-month low is $128.26 and its 12-month high is $175.91. The company’s 50-day moving average is $158.31 and its 200-day moving average is $149.17. The company has a quick ratio of 0.83, a current ratio of 0.93 and a debt to equity ratio of 3.77. The company has a market cap of $294.54 billion, a price/earnings ratio of 22.24, a P/E/G ratio of 3.54 and a beta of 0.69.
AbbVie (NYSE: ABBV – Get Rating) last reported quarterly earnings data on Friday, October 28. The company reported his EPS of $3.66 for the quarter, beating analyst consensus expectations of $3.56 for him by $0.10. AbbVie’s net profit margin was 23.19% and return on equity was 155.88%. The company’s revenue for the quarter was $14.81 billion, compared with analyst estimates of $14.95 billion. During the same period last year, the business earned him $3.33 per share. AbbVie revenue increased 3.3% compared to the same period last year. Research analysts expect AbbVie to post 13.98 earnings per share for the current financial year.
AbbVie increases dividend
The company recently announced a quarterly dividend payable on Wednesday, February 15th. Investors of record on Friday, January 13 will receive a dividend of $1.48 per share. This represents his $5.92 dividend and his 3.55% yield on an annualized basis. This is up from AbbVie’s previous quarterly dividend of $1.41. The ex-dividend date for this dividend is Thursday, January 12. AbbVie’s payout percentage is currently 75.30%.
In other AbbVie news, EVP Timothy J. Richmond sold 42,370 shares in the company in a transaction that took place on Monday, December 12th. The shares sold for an average of $163.44 for a total of $6,924,952.80. Following the closing of the transaction, the Executive Vice President now owns 13,837 shares of the Company’s stock valued at approximately $2,261,519.28. The transaction was disclosed in SEC filings available at this link. A corporate insider owns his 0.08% of the company’s shares.
Hedge funds join AbbVie
Institutional investors recently changed their holdings in the company. Retirement Income Solutions Inc bought a new position in AbbVie for $204,000 in the first quarter. Maple Capital Management Inc. purchased approximately $221,000 worth of his new AbbVie stock in the first quarter. Algert Global LLC purchased new shares of his AbbVie stock worth approximately $281,000 in the third quarter. BCK Partners Inc. purchased his new stake in AbbVie worth approximately $298,000 in the first quarter. Finally, Worth Asset Management LLC purchased approximately $407,000 worth of new AbbVie stock in the first quarter. Currently 67.71% of the shares are owned by institutional investors.
AbbVie Inc discovers, develops, manufactures and markets pharmaceuticals worldwide. The company offers Humira, a therapy given as an injection for autoimmune diseases and intestinal Behcet’s disease. SKYRIZI for the treatment of moderate-to-severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate-to-severe active rheumatoid arthritis in adult patients. IMBRUVICA, which treats adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adult CLL or SLL. MAVYRET treats patients with chronic HCV genotype 1-6 infection.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to firstname.lastname@example.org.
Before you consider AbbVie, listen to this.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and AbbVie wasn’t on the list.
AbbVie currently has a “Hold” rating among analysts, but top-rated analysts believe these five stocks are better buys.
See 5 stocks here